Dr. Jim Mitchell

Jim MitchellKansas Bioscience Authority - Partners in Bioscience Growth

Kansas Bioscience Authority
...
James MitchellDirector of Heartland BioVenturesand Director of Investments

Jim Mitchell received his Ph.D. in biochemistry from Iowa State University in 1979.During his subsequent 28-year industrial career, he held R&D and operations positions in six different companies, including his most recent position as vice president for pharmaceutical R&D at Hospira, Inc.

Dr. Mitchell holds several patents in drug delivery and protein chemistry and has been directly involved with the successful development and launch of more than 50 proprietary and generic products.He serves on several advisory boards and has worked at the state level to foster the funding of innovative research across a broad range of technology-based products.

His multi-company R&D and management experience, ranging from drug discovery through commercialization, provides a unique prospective related to the balance between innovation, resource utilization, and R&D cycle times in achieving sustained earnings growth.

Jim Mitchell, VP Pharmaceutical Development - Hospira Inc.
...
Dr. Mitchell: To address what biotech can bring to pharma, I believe that biotech companies can bring novel technological improvements and great enthusiasm. However, a healthy dose of reality is also required.
...
Dr. Mitchell: Big pharma companies have offices for technology assessment, but you can also enter directly via the business development team.
...
Dr. Mitchell: Pfizer will look at early stage companies, whereas Hospira tends to consider companies in Phase II or beyond.
...
Dr. Mitchell: We have talked about credibility, having a solid data package based on development stage, how to get in the door, and how to define business relationships in pursuing partnerships.
...
Jim Mitchell, Hospira Inc. Jim Mitchell received his Ph.D. in Biochemistry from Iowa State University in 1979. During his 28-year industrial career, he has held various R&D and Operations positions in 6 different companies, including his current position as Vice President Pharmaceutical R&D at Hospira, Inc. Jim holds several patents in the areas of drug delivery and protein chemistry and has been directly involved with the successful development and launch of over 50 proprietary and generic products. He has and continues to serve on several advisory boards and has worked at the state level to foster the funding of innovative research across a broad range of technology-based products. His multi-company R&D and management experience, ranging from drug discovery through commercialization, provides a unique prospective related to the balance between innovation, resource utilization and R&D cycle times in achieving sustained earnings growth.

Jim Mitchell
...
Jim MitchellDirector of Heartland BioVentures and Director of Investments

Jim MitchellDirector of Commercialization Services, Heartland BioVentures

Panelists: Jim Mitchell, VP Pharmaceutical Development Hospira Inc.

Others attending were Tom Thornton, Jan Katterhenry, Jim Mitchell, Chuck Willis, Bret Healy, Gary Micheel and Marsh LoScalzo all of KBA.
...
Dr. Mitchell gave an Operational Summary of the Heartland BioVentures plan. He discussed the purpose of the document, HBV’s mission, organization, program emphases and operational milestones as well as an outline for a short-term plan that will drive HBV’s core focus areas and budget for FY 2009. He noted that the plan would include strategies related to: Commercialization, Business Development, and Capital Formation.
...
The KBA recommendation is to approve the POCI program; authorize Heartland Bioscience staff (Jim Mitchell) to develop and implement the program in conjunction with the HBV Advisory Board; allocate $1.5 million from previously committed funds available to Heartland BioVentures to implement the program.

Dr. Mitchell gave an Operational Summary of the Heartland BioVentures plan. He discussed the purpose of the document, HBV's mission, organization, program emphases and operational milestones as well as an outline for a short-term plan that will drive HBV's core focus areas and budget for FY 2009. He noted that the plan would include strategies related to: Commercialization, Business Development, and Capital Formation.
...
The KBA recommendation is to approve the POCI program; authorize Heartland Bioscience staff (Jim Mitchell) to develop and implement the program in conjunction with the HBV Advisory Board; allocate $1.5 million from previously committed funds available to Heartland BioVentures to implement the program.

Others attending were Tom Corcoran, Tom Thornton, Jan Katterhenry, Jim Mitchell, Chad Bettes, Mary Cummings and Marsh LoScalzo all of KBA.
...
Heartland BioVentures Presentation: Mr. Thornton introduced Jim Mitchell, the KBA’s director of investments, who provided an overview of Heartland BioVentures.

Jim Mitchell, VP, Pharma Development, Hospira